Our overall goal was to evaluate the effect of CS-6253 (CS) treatment on apoE levels, AD-relevant pathology, and behavior in mice that express human APOE. Therefore, we utilized EFAD mice that express human APOE4 (E4FAD) or APOE3 (E3FAD) and overproduce Aβ42. The gene discussed is APOE; the disease is Alzheimer disease.